Abla A. Creasey

4.7k total citations · 1 hit paper
42 papers, 3.1k citations indexed

About

Abla A. Creasey is a scholar working on Immunology, Hematology and Molecular Biology. According to data from OpenAlex, Abla A. Creasey has authored 42 papers receiving a total of 3.1k indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Immunology, 12 papers in Hematology and 11 papers in Molecular Biology. Recurrent topics in Abla A. Creasey's work include Blood Coagulation and Thrombosis Mechanisms (11 papers), Sepsis Diagnosis and Treatment (11 papers) and Immune Response and Inflammation (5 papers). Abla A. Creasey is often cited by papers focused on Blood Coagulation and Thrombosis Mechanisms (11 papers), Sepsis Diagnosis and Treatment (11 papers) and Immune Response and Inflammation (5 papers). Abla A. Creasey collaborates with scholars based in United States, Netherlands and Japan. Abla A. Creasey's co-authors include R. Yamamoto, Leo S. Lin, Alvin Chang, L. B. Hinshaw, TC Wun, Fletcher B. Taylor, Larry P. Feigen, Alice M. Wang, Martha Ladner and Mark David and has published in prestigious journals such as Science, Proceedings of the National Academy of Sciences and Journal of Clinical Investigation.

In The Last Decade

Abla A. Creasey

42 papers receiving 2.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Molecular Cloning of the Complementary DNA for Human Tumor Necrosis Factor

1985 547 citations Alice M. Wang, Abla A. Creasey et al. Science profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Abla A. Creasey United States	26	1.0k	999	776	766	410	42	3.1k
Zoltán Lászik United States	27	1.0k 1.0×	864 0.9×	998 1.3×	759 1.0×	286 0.7×	87	3.9k
G. Müller‐Berghaus Germany	31	886 0.8×	1.8k 1.8×	626 0.8×	435 0.6×	637 1.6×	111	4.7k
Patricia C. Liaw Canada	35	1.7k 1.6×	1.1k 1.1×	1.1k 1.4×	1.0k 1.3×	520 1.3×	95	4.5k
N. Semeraro Italy	29	534 0.5×	1.5k 1.5×	538 0.7×	629 0.8×	557 1.4×	142	3.5k
Naomi L. Esmon United States	27	2.2k 2.1×	1.9k 1.9×	919 1.2×	578 0.8×	504 1.2×	45	4.5k
Jef Arnout Belgium	33	556 0.5×	1.6k 1.6×	570 0.7×	201 0.3×	311 0.8×	85	4.1k
BC Furie United States	25	572 0.5×	1.4k 1.4×	728 0.9×	161 0.2×	292 0.7×	39	3.1k
Robert L. Evans United States	27	1.6k 1.5×	278 0.3×	684 0.9×	203 0.3×	339 0.8×	87	4.2k
Gerhard Dickneite Germany	32	358 0.3×	1.2k 1.2×	397 0.5×	319 0.4×	356 0.9×	111	3.1k
E. Regoeczi Canada	33	286 0.3×	968 1.0×	1.2k 1.5×	234 0.3×	293 0.7×	140	3.4k

Countries citing papers authored by Abla A. Creasey

Since Specialization

Citations

This map shows the geographic impact of Abla A. Creasey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Abla A. Creasey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Abla A. Creasey more than expected).

Fields of papers citing papers by Abla A. Creasey

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Abla A. Creasey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Abla A. Creasey. The network helps show where Abla A. Creasey may publish in the future.

Co-authorship network of co-authors of Abla A. Creasey

This figure shows the co-authorship network connecting the top 25 collaborators of Abla A. Creasey. A scholar is included among the top collaborators of Abla A. Creasey based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Abla A. Creasey. Abla A. Creasey is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Caras, Ingrid W., Lila R. Collins, & Abla A. Creasey. (2021). A Stem Cell Journey in Ophthalmology: From the Bench to the Clinic. Stem Cells Translational Medicine. 10(12). 1581–1587. 7 indexed citations

Creasey, Abla A., Glyn Stacey, Kapil Bharti, Yoji Sato, & A. S. Lubiniecki. (2019). A strategic road map to filing a Biologics License Application for a pluripotent stem cell derived therapeutic product. Biologicals. 59. 68–71. 10 indexed citations

Jamieson, Catriona, Maria T. Millan, Abla A. Creasey, et al.. (2018). CIRM Alpha Stem Cell Clinics: Collaboratively Addressing Regenerative Medicine Challenges. Cell stem cell. 22(6). 801–805. 5 indexed citations

Li, Shu, et al.. (2012). Enhanced Bioavailability of a Poorly Water-Soluble Weakly Basic Compound Using a Combination Approach of Solubilization Agents and Precipitation Inhibitors: A Case Study. Molecular Pharmaceutics. 9(5). 1100–1108. 36 indexed citations

Laterre, Pierre-François, Steven M. Opal, Edward Abraham, et al.. (2009). A clinical evaluation committee assessment of recombinant human tissue factor pathway inhibitor (tifacogin) in patients with severe community-acquired pneumonia. Critical Care. 13(2). R36–R36. 35 indexed citations

Abraham, Edward, Konrad Reinhart, Petr Svoboda, et al.. (2001). Assessment of the safety of recombinant tissue factor pathway inhibitor in patients with severe sepsis: A multicenter, randomized, placebo-controlled, single-blind, dose escalation study. Critical Care Medicine. 29(11). 2081–2089. 193 indexed citations

Matyal, Robina, et al.. (2001). Extremely low doses of tissue factor pathway inhibitor decrease mortality in a rabbit model of septic shock. Intensive Care Medicine. 27(8). 1274–1280. 20 indexed citations

Creasey, Abla A.. (1999). New Potential Therapeutic Modalities: Tissue Factor Pathway Inhibitor. 3(2). 173–182. 26 indexed citations

Creasey, Abla A., et al.. (1998). Delayed Treatment with Recombinant Human Tissue Factor Pathway Inhibitor Improves Survival in Rabbits with Gram‐Negative Peritonitis. The Journal of Infectious Diseases. 177(3). 668–676. 69 indexed citations

10.

Johnson, Kirk W., et al.. (1998). Potential Mechanisms for a Proinflammatory Vascular Cytokine Response to Coagulation Activation. The Journal of Immunology. 160(10). 5130–5135. 176 indexed citations

11.

Goldfarb, Roy D., Dana Glock, Kirk W. Johnson, et al.. (1998). RANDOMIZED, BLINDED, PLACEBO-CONTROLLED TRIAL OF TISSUE FACTOR PATHWAY INHIBITOR IN PORCINE SEPTIC SHOCK. Shock. 10(4). 258–264. 37 indexed citations

12.

Johnson, K, et al.. (1996). The proinflammatory cytokine response to coagulation and endotoxin in whole blood. Blood. 87(12). 5051–5060. 98 indexed citations

13.

Creasey, Abla A., Alvin Chang, Larry P. Feigen, et al.. (1993). Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock.. Journal of Clinical Investigation. 91(6). 2850–2860. 446 indexed citations

14.

Boer, Jan Paul de, Abla A. Creasey, Dorina Roem, et al.. (1993). Activation of the complement system in baboons challenged with live Escherichia coli: correlation with mortality and evidence for a biphasic activation pattern. Infection and Immunity. 61(10). 4293–4301. 54 indexed citations

15.

Silberstein, David S., et al.. (1990). A serum factor that suppresses the cytotoxic function of cytokine-stimulated human eosinophils.. The Journal of Experimental Medicine. 171(3). 681–693. 5 indexed citations

16.

Geigert, John, et al.. (1987). Potency Stability of Recombinant (Serine-17) Human Interferon-β. Journal of Interferon Research. 7(2). 203–211. 13 indexed citations

17.

Fendly, B M, Karen Toy, Abla A. Creasey, et al.. (1987). Murine Monoclonal Antibodies Defining Neutralizing Epitopes on Tumor Necrosis Factor. Hybridoma. 6(4). 359–370. 14 indexed citations

18.

Creasey, Abla A., et al.. (1986). Cures and partial regression of murine and human tumors by recombinant human tumor necrosis factor.. PubMed. 46(11). 5687–90. 110 indexed citations

19.

Wang, Alice M., Abla A. Creasey, Martha Ladner, et al.. (1985). Molecular Cloning of the Complementary DNA for Human Tumor Necrosis Factor. Science. 228(4696). 149–154. 547 indexed citations breakdown →

20.

Creasey, Abla A., et al.. (1983). Growth Regulation of Melanoma Cells by Interferon and (2′-5′)Oligoadenylate Synthetase. Molecular and Cellular Biology. 3(5). 780–786. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact